clear segregation. Overall treatment results were similar to delayed treatment ones. CONCLUSION: No statistic differences were found between treatments in acute effectiveness, and hence cost minimization analysis was only considered. GR showed to be more cost-effective than ON in delayed and overall emesis treatment.
Garrison LP,Veenstra DL University of Washington, Seattle, WA, USA OBJECTIVES: Trastuzumab (T) was recently approved to treat women with HER2+ early breast cancer (eBC) following earlier approval for metastatic breast cancer (mBC). The objective is to estimate the potential aggregate economic value and the incremental cost-utility ratio (ICUR) over T's life cycle in five major European countries from 2000 to 2020. METHODS: The projected life cycle ICUR was estimated by combining the ICURs of T in eBC and mBC in a dynamic life cycle (DLM) model. The model also projects the economic value to society, defined as monetized cumulative net quality-adjusted life years (QALYs) gained minus net life-cycle treatment costs. Using indicationspecific ICURs (€43,000 per QALY in mBC and €15,000 per QALY in eBC) and epidemiological projections of disease incidence in Germany, France, UK, Italy, and Spain, the projected life cycle ICUR and cumulative economic value were estimated, discounting at 3.5%. RESULTS: We project a relative increase in the number of women with HER2+ eBC vs. HER2+ mBC-a ratio of 3.4 in 2020 up from 2.1 in 2000. Over this period, the projected overall mean ICUR was €18,000 per QALY with a total of 800,000 discounted QALYs gained. Scenario analysis was performed for alternative use rates and ICURs. When benchmarked against potentially acceptable values per QALY of €50,000 or €100,000, the total projected economic value of T treatment would range from €30 to €70 billion, respectively. CONCLU-SION: Application of a DLM estimation approach to the case of trastuzumab demonstrates that: 1) the economic value of a product can change due to life-cycle innovation, and 2) typical static, indication-specific cost-effectiveness models do not account for the interdependence of drug development and adoption decisions over the life cycle. This raises important policy questions about the appropriate perspective-static vs. dynamic-and reimbursement for an innovative product whose economic value changes over time.
PCN27

COST-EFFECTIVENESS OF HUMAN INTERFERON-ALPHA AS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTED CUTANEOUS MALIGNANT MELANOMA IN STAGE IIB & III
Kasteng F 1 , Stadler R 2 , Wagenius G 3 , Lundkvist J 1 1 i3 Innovus, Stockholm, Sweden, 2 Academic Medical Centre, Minden, Germany, 3 Uppsala University Hospital, Uppsala, Sweden OBJECTIVES: The objective of this economic evaluation was to estimate the cost-effectiveness of HuIFN-á as adjuvant treatment for patients with resected cutaneous malignant melanoma in stage IIb-III in a Swedish setting. METHODS: The economic evaluation is based on a prospective multicentre study, in which 252 patients with totally resected cutaneous melanoma in stage II-IV (whereof 158 high-risk patients with melanoma in stage IIb-III) were randomised to induction treatment with dacarbazine (DTIC) followed by six months adjuvant treatment with low-dose natural human interferon alpha (HuIFN-á) versus no adjuvant treatment. A Markov model was developed to assess the costs and clinical outcomes of DTIC/HuIFN-á compared with no adjuvant treatment. Time-to-progression and overall survival were based on data from the clinical study. The model compares two groups of patients, 54 years old at base-line, and adopts a life-long horizon. The primary clinical outcome measure is quality-adjusted life years (QALYs) gained. Direct medical costs were included in the analysis. An additional analysis was performed that included costs of added years of life for the Swedish population. Cost and outcome data were discounted with a 3% annual rate. Sensitivity analyses were performed to test the stability of the base case results. RESULTS: The economic analysis showed that adjuvant treatment with HuIFN-á for stage IIb-III melanoma patients resulted in €8200 higher costs and 2.5 additional QALYs, leading to an incremental cost per QALY gained of €3300 compared to no adjuvant treatment. Including costs of added years of life increased the cost per QALY gained to about €21,100. The results were stable in sensitivity analyses. CONCLUSION: The economic evaluation indicates that adjuvant treatment with HuIFN-á is cost-effective for patients with resected cutaneous malignant melanoma in stage IIb-III.
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